Oct 22, 2014 | Digital Pathology, Instruments & Equipment, Laboratory Management and Operations, Laboratory News, Laboratory Operations, Laboratory Pathology
Developed to detect pathogens missed in wounds of soldiers, this technology was licensed to a company for development into a test for use by clinical laboratories
Diagnostic technology developed for rapid detection of pathogens in the wounds of soldiers has been licensed to a private company that intends to use it to create new medical laboratory tests. This new technology is capable of identifying thousands of bacteria and viruses in a single test.
Scientists at the Lawrence Livermore National Laboratory developed what is called the Lawrence Livermore Microbial Detection Array (LLMDA). Within 24 hours, this single test can detect multiple viruses and bacteria. The LLMDA technology has been licensed to St. Louis, Missouri-based MOgene LC, a supplier of DNA microarrays, according to a report published by UC Health. (more…)
Sep 29, 2014 | Digital Pathology, Instruments & Equipment, Laboratory Management and Operations, Laboratory News, Laboratory Pathology
This technology could provide medical labs a quick, cost-effective way to diagnose methicillin-resistant Staphylococcus aureus
Even as in vitro diagnostics manufacturers are bringing rapid molecular tests to market that can identify infectious diseases within hours, a research collaboration involving a major university and a medical laboratory at an air force base has demonstrated the ability to identify antibiotic-resistant strains of Staphylococcus in just minutes.
This innovative research is being done by Auburn University’s College of Veterinary Medicine and clinical laboratory professionals at Keesler Air Force Base. Funding is by the U.S. Air Force. This research was of particular interest to the military because the risk for Staph infection increases when individuals are subjected to unhygienic conditions in close quarters. (more…)
Nov 23, 2012 | Laboratory Hiring & Human Resources, Laboratory News, Laboratory Pathology
Hot competition for genetic testing market share is a signal to medical laboratories to ramp up their molecular and genetic testing capabilities
Financial analysts see something of an “old west” style shootout on the horizon for genetic testing in the clinical laboratory testing market. Market leaders in next-generation gene sequencing are prepared to use acquisitions to build dominant shares in a gene testing market that experts say could hit $25 billion by 2022.
Reporters at Bloomberg Businessweek believe that San Diego-based Illumina, Inc. (NASDAQ: ILMN) is girding up to take on industry giant Roche Holding AG (ROG.VX). Both Illumina and Life Technologies Corp. (NASDAQ:LIFE) are buying up smaller players in the gene testing market.
These two market leaders in DNA sequencing equipment have played important roles in revolutionizing genetic testing. Now, they intend to stake out a share of the fast-growing genetic diagnostics market themselves, a recent Businessweek story reported. (more…)
Apr 27, 2012 | Instruments & Equipment, Laboratory Management and Operations, Laboratory News, Laboratory Operations, Laboratory Pathology, Management & Operations
Trend from reductionism to holistic biomedicine means clinical laboratories and pathologists should expect increased multiplex testing
Systems biology (SB) is a rapidly-evolving area of research that, by itself, could greatly expand the need for multiplex testing performed by clinical laboratories. But systems biology has yet to catch the full attention of either the media or Wall Street.
That may soon change. Despite the complexity of human metabolic systems, experts in systems biology are making progress in identifying the myriad of metabolic channels that collectively can be used to diagnose disease and identify appropriate therapies. These are auspicious developments for medical laboratory managers and pathologists.
Probably no single individual has done more to advance the field of systems biology than Leroy Hood, M.D., Ph.D. In 2000, he co-founded the Institute for Systems Biology (ISB) in Seattle, Washington and his colleagues engaged scientists across a number of fields to study the metabolic processes of humans and other organisms.
(more…)
Mar 19, 2012 | Laboratory Management and Operations, Laboratory Operations, Laboratory Pathology
Annual growth rates of 11% or more is predicted for molecular diagnostics in coming years
Just as consolidation and acquisitions reshaped the in vitro diagnostics (IVD) manufacturing industry and concentrated market share among just a handful of multi-billion dollar IVD giants, a similar consolidation can be seen in the molecular diagnostics sector. Today it is estimated that just nine global companies control 75% of the molecular diagnostics market.
That market concentration means clinical laboratories and anatomic pathology groups have a just a handful of primary vendors from which to purchase many of the molecular diagnostic assays and genetic tests that are used most frequently in clinical care.
Frost and Sullivan published a detailed study about the molecular diagnostics marketplace. The consulting firm estimated that worldwide sales of molecular diagnostics totaled $4.1 billion in 2010. By contrast, total IVD sales globally were about $48 billion in 2010. That total includes the routine, reference, and esoteric test kits, reagents, and supplies used every day by medical laboratories.
(more…)
